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Abstract
OBJECTIVE—To determine whether specific macrophage immune functions of the newly born
are insensitive to the actions of therapeutic levels of dexamethasone (DEX), previously measured
in infants with bronchopulmonary dysplasia (BPD), compared to betamethasone (BETA) and
exogenous or endogenous interleukin-10 (IL-10).
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STUDY DESIGN—Macrophages were differentiated from cord blood monocytes (N=18). A
serial dose response (around 10−8M), in vitro study was used to examine the effect of DEX, BETA
and IL-10, on pro-inflammatory (PI) cytokine release, phagocytosis and respiratory burst.
RESULTS—Exogenous IL-10 (10−8M) significantly (p<0.05) inhibited the endotoxin-stimulated
release of IL-6, IL-8 and tumor necrosis factor by 63% to 82% with no significant effect by DEX
and BETA. There was no inhibition by these 3 agents at 10−8M on phagocytosis and respiratory
burst. Inhibition of endogenous IL-10 with a monoclonal antibody significantly raised endotoxinstimulated cytokine release by at least 4 fold.
CONCLUSION—Macrophages were relatively insensitive to therapeutic levels of DEX and
BETA with regard to PI cytokine release. This study provides rationale for translational,
preclinical research using airway instillation of IL-10 for the treatment of BPD.
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INTRODUCTION
Bronchopulmonary dysplasia (BPD) is one of the most important causes of morbidity and
mortality from neonatal intensive care units 1. Persistent lung inflammation, with an
imbalance of pro-inflammatory versus anti-inflammatory mediators, plays a central role in
the pathogenesis of BPD along with an arrest of lung growth 2, 3, 4, 5. Late anti-inflammatory
therapy with dexamethasone (DEX) has been the mainstay of therapy for neonates that are at
high risk for severe BPD and/or death 6. The optimal dose of postnatal dexamethasone that
reduces the incidence of BPD without increasing neurodevelopmental injury is not known
but appears to occur when higher cumulative doses of dexamethasone are administered 7.
DEX treatment for BPD is only partially effective and may be associated with potential
serious short and long term side effects, therefore alternative therapies are being actively
investigated 8, 9.
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During the early evolution of BPD, there are abnormally high levels of polymorphonuclear
leukocytes followed by monocytes recruited into the lung 10, 11, 12, 13. Circulating
monocytes are the principal precursor of alveolar macrophages 14. By one to two weeks
after birth, the principal inflammatory cells in the airway fluid of babies with evolving BPD
are macrophages associated high levels of pro-inflammatory cytokines such as interleukin-6
(IL-6), interleukin-8 (IL-8) and tumor necrosis factor (TNF) 15. In contrast, the potent antiinflammatory cytokine (IL-10) is either absent or detected at very low levels from airway
fluid of babies developing BPD 16, 17, 18. Interestingly, previous work has shown that the
endotoxin-stimulated monocyte of the newborn, the cell precursor of the alveolar
macrophage is insensitive to glucocorticoids compared to exogenous interleukin-10 (IL-10)
on an equimolar basis, in the therapeutic dose range of dexamethasone for BPD 19, 20.
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Accordingly, we hypothesized that for macrophages of the newly born: 1) endogenous and
exogenous IL-10 produces a greater inhibition of pro-inflammatory cytokine release
compared to equimolar levels of dexamethasone and betamethasone; but 2) these three antiinflammatory agents, at therapeutic levels of DEX for BPD, may have an unwanted
inhibitory effect on two major macrophage innate immune functions, phagocytosis and
respiratory burst.

MATERIALS AND METHODS
Subjects
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Cord blood (approximately 60 ml) was obtained from placentas after elective, term cesarean
section deliveries, without medical complications. Blood was collected in heparinized
preservative –free tubes for transport to the laboratory, followed by immediate cell isolation.
The study was approved by the Internal Review Board of the North Shore-Long Island
Jewish Health System. Consent was not required.
Cell Isolation and Culture
Monocytes were isolated from cord blood as previously described 19, 20 with >95% viability
by trypan blue inclusion and >90% (CD14+) purity by flow cytometry. Briefly, peripheral
blood mononuclear leukocytes (monocytes and lymphocytes) were isolated from cord blood
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using Ficoll-Paque PLUS (Amersham-GE Healthcare, Piscataway, NJ) density
centrifugation. Monocytes were separated from lymphocytes using Percoll (Amersham-GE
Healthcare) and the MACS monocyte isolation kit II supplemented with CD15 microbeads
(Miltenyi Biotec, Auburn, CA). Monocytes were resuspended in RPMI at 1×106 cells per
well. Monocytes were allowed to adhere for one hour at 37°C.
Macrophage Differentiation
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RPMI media was removed and adherent monocytes were re-incubated at 37°C + 5% CO2
with RPMI 1640 supplemented with penicillin-streptomycin, 10% fetal calf serum,
glutamine, and granulocyte macrophage colony-stimulating factor (GM-CSF, 10ng/ml) for 7
days 21. Media was changed on Day 4. Cells were examined histologically for
differentiation using a Zeiss Apotome inverted microscope at 20x resolution. At the time of
each experiment, cell viability was assessed by the 3-(4,5-dimethylthiazol-2-yl)-diphenyl
tetrazolium bromide (MTT) assay.
Cytokine Release and Inhibition
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Macrophages (N=6 cord blood samples) were pre-incubated for 1 h with PBS vehicle or
serial concentrations of recombinant IL-10 (R&D Systems, Minneapolis, MN),
dexamethasone (DEX), or betamethasone (BETA) (American Regent Shirley, NY). For the
dose response experiments, equimolar, serial doses of 10−10M to 10−6M of these 3 agents
were used, based on work demonstrating that the plasma concentration range of
dexamethasone in neonates being treated for BPD was 10−8 to 10−7 M. 22, 23 Macrophages
were then stimulated with LPS (1ng/ml in PBS) (Sigma-Aldrich, St. Louis, MO) for 4 and18
h. PBS was used as a negative control. Separately, macrophages were incubated with antiIL-10 antibody or IgG as a control (R&D Systems, Minneapolis, MN) prior to LPS
stimulation to determine the effect of endogenous IL-10 on PI cytokine release. For the time
course experiments (N=7), macrophages were pre-incubated with equimolar concentrations
(10−8M) of IL-10, DEX or BETA for 1 h, then stimulated with LPS (1ng/ml) for 4 and 18 h.
Cell culture supernatant was collected and analyzed for cytokine release of IL-6, IL-8 and
TNF alpha using ELISA kits (R&D Systems, Minneapolis, MN).
Phagocytosis
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Macrophage phagocytosis was measured by the CytoSelect™ 96-Well Phagocytosis
Zymosan Colorimetric Assay (Cell Biolabs Inc, San Diego, CA), according to the
manufacturer’s protocol. Briefly, monocytes (N=7 cord blood samples) were incubated in 96
well plates (5×105 cells/well) and differentiated into macrophages as described above. At 7
days, differentiated macrophages were pre-incubated for 1h at 37°C with 10−8M IL-10,
DEX or BETA, with PBS as a control. Cells were then stimulated with prelabeled zymosan
(5×106 particles per well) for 2 h. Engulfed zymosan was detected at an absorbance of 405
nanometers.
Respiratory Burst
Monocytes (N=5 cord blood samples) (105 cells/well) were incubated in black, clear bottom
96 well plates and differentiated into macrophages as described above. Macrophage
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respiratory burst was measured by using the OxiSelect™ Intracellular ROS Assay Kit (Cell
Biolabs Inc., San Diego, CA). Differentiated macrophages were washed with PBS and preincubated for 1 h at 37°C with 10−8M IL-10, DEX or BETA, with PBS as a control. At 30
min, cell permeable fluorogenic probe 2′,7″-dichlorohydrofluoroescin diacetate (DCFH-DA)
was added to the cell media. After 1 h cells were washed and stimulated with Zymosan A
from Saccharomyces cerevisiae (0.5 mg/ml)(Sigma-Aldrich, St. Louis, MO). Cells
incubated with hydrogen peroxide served as a positive control during the assay. The DCFH
oxidized to highly fluorescent 2′7′-Dichlorohydrofluoroscein (DCF) by ROS generated
during the incubation with zymosan, was read at 0 h (baseline) and 1 h, using a fluorescent
plate reader with 480nm excitation and 530nm emission.
Statistical Analyses
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Data was analyzed by one way ANOVA with a Bonferroni correction for multiple
comparisons over time, between concentrations of inhibitors and for the effects of IL-10 and
glucocorticoids on phagocytosis and respiratory burst. An overall p value of 0.05 was
considered statistically significant.

RESULTS
Figure 1 demonstrates the effect of serial increases DEX on release of three proinflammatory cytokines over 18 h from endotoxin-stimulated macrophages of the newborn.
The only significant inhibition was observed for IL-8 release when macrophages were
pretreated with DEX at 10−6M. Figure 2 demonstrates the results of the same dose-response
design for BETA. However a significant inhibition of IL-8 and TNFα, was observed at
10−7M.
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Figure 3 demonstrates the effect of serial increases of IL-10 on the same 3 cytokines
released from endotoxin-stimulated macrophages of the newborn over 18 h. Release of all 3
cytokines were inhibited by over 50% with IL-10 at 10−10M and with further inhibition
occurred to over 80% with 10−8M. In addition, this figure demonstrates the effect of
pretreatment of endotoxin-stimulated macrophages with a monoclonal antibody to IL-10
(IL-10 mAb) and IgG as a control. Over a 5 fold increase in cytokine release was observed
over 18 h for each cytokine with pre-incubation of macrophages with IL-10 mAb before
LPS stimulation. There was no effect of pre-incubation of IgG (as a control for IL-10 mAb)
on the release of these cytokines compared to endotoxin alone.
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The time-related effects of equimolar levels (10−8M) of DEX, BETA, and exogenous IL-10
on LPS-stimulated macrophages (106 cells) release for 3 pro-inflammatory cytokines are
shown in Figure 4. Cytokine levels at 4 and 18 h of LPS stimulation with an antiinflammatory agent were compared to cells exposed to LPS alone. DEX had no effect on
any cytokine release. Betamethasone inhibited IL-8 release by 25% at 18 h. Exogenous
IL-10 inhibited the release of all three cytokines at 4 h (IL-6 by 84%, IL-8 by 74%, and TNF
by 64%). At 18 h, exogenous IL-10 inhibited the release of the 3 pro-inflammatory
cytokines (IL-6 by 82%, IL-8 by 72%, and TNF by 83%).
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There was no effect of 10−8M DEX, BETA or IL-10 on phagocytosis as shown in Figure 5.
A marked effect was observed with cytochalasin D. There was also no effect of 10−8 M
DEX, BETA or IL-10 on respiratory burst as shown in Figure 6. Zymosan alone produced a
significant increase in superoxide release as measured by DCF.

DISCUSSION
The present study used macrophages derived from cord blood of the newly born, to compare
the effect of equimolar levels of exogenous IL-10 versus dexamethasone and betamethasone
on pro-inflammatory cytokine release, phagocytosis and respiratory burst. At plasma levels
of dexamethasone detected in babies being treated for BPD (approximately 10−8 M), only
IL-10 produced a significant reduction in pro-inflammatory cytokine release and there was
no effect of these three agents on phagocytosis and respiratory burst.
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By 10 days after birth in the evolution of BPD, macrophages are the principal cells found
within the airway fluid and the major source of pro-inflammatory (PI) cytokines 15. IL-10,
the potent anti-inflammatory (AI) cytokine can be produced by MONOs and macrophages
but not by PMNs of the newborn 24. However, IL-10 is absent or found at very low levels in
the airway fluid of babies with evolving BPD suggesting an imbalance in PI and AI
cytokines as one underlying mechanism of this disorder 16, 17, 18
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MONOs, the principal precursors of alveolar macrophages of the newborn demonstrate a
striking insensitivity to DEX compared to IL-10 at therapeutic levels of DEX 20. In the
present study, under similar experimental conditions to previous monocyte studies, we found
a similar glucocorticoid insensitivity observed for macrophages of the newborn. This
insensitivity may explain, in part, why the beneficial anti-inflammatory effect of exogenous
DEX in present day treatment of BPD is only partly effective6. Corticosteroid insensitivity
has been reported in several common and serious, adult pulmonary disorders, including
chronic obstructive pulmonary disease and severe asthma 25. Patients with asthma, who also
smoke, are insensitive to corticosteroids 25. Research directed to mononuclear cells and
macrophages have started to uncover mechanisms associated with corticosteroid
insensitivity 25, 26, 27, 28.
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Due to the harmful side effects and limited efficacy of corticosteroids, alternative therapy
for BPD is needed. Novel anti-inflammatory therapy for the prevention or treatment of BPD,
should be selective in its effect on immune functions of the newborn, so as to minimize the
risk of the newborn to infection. We found that IL-10 at 10−8 M resulted in marked
inhibition of PI cytokine release in macrophages unlike the corticosteroids. Neither IL-10,
DEX nor BETA had. significant effects on the important macrophage functions of
phagocytosis and respiratory burst. In previous work IL-10 was found to be a deactivator or
activator of phagocytosis depending on the neutrophil or monocyte cell type from adults and
concentration of IL-10 29. In mouse peritoneal macrophages, glucocorticoids enhanced the
respiratory burst via a nongenomic mechanism30.
The present in vitro studies used clinical benchmarks for LPS stimulation and the testing of
equimolar levels of the three anti-inflammatory agents on macrophage functions. LPS was
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used at a concentration of 1ng/ml to benchmark against levels found in amniotic fluid during
the fetal inflammatory response syndrome (0.6 to 48ng/ml)31. Measurements of plasma
DEX levels during the treatment BPD were in the 10−7 to 10−8 M range in an era when
relatively higher doses of DEX were used to treat BPD on a long tapering dose
regimen 22, 23. All dose comparisons in the present study for IL-10, DEX and BETA were
made on an equimolar basis. Among the many pro-inflammatory cytokines found in airway
fluid of babies with evolving BPD, IL-6 and IL-8 are found at the highest levels by 10
days 15, 16. No significant inhibition of these PI cytokines was observed at 10−8 M by DEX
and BETA. IL-1β has also been also found in the airway of neonates developing BPD 15, 16,
however interestingly, we could not detect IL-1β under our experimental conditions (data
not shown). Other investigators have found variable production of IL-1β by macrophages 32.
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A limitation of this study may be the use of cord blood from healthy term infants after
elective cesarean section since BPD occurs more frequently in preterm infants after
respiratory distress syndrome than term infants with hypoxic respiratory failure 1, 33. The
design for the present study required the collection of enough volume of blood for monocyte
isolation. The design also avoided the potential confounding effects of antenatal steroids,
maternal medications and maternal disorders associated with prematurity that are not present
when corticosteroids are used for BPD, usually beyond several weeks after birth34. This
study does not address whether there are developmental differences in macrophage
insensitivity to glucocorticoids or Il-10. Additionally, we chose to use in vitro differentiation
of monocytes to study macrophages because alveolar macrophages of the premature infants
could not provide enough cells to perform the present studies. However, cell surface
antigens and functions of GM-CSF-induced, monocyte-derived macrophages from adults
have almost identical characteristics as alveolar macrophages from adults 21.
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In conclusion, the present in vitro study demonstrates a relative insensitivity of DEX, and to
a lesser degree BETA, with regard to pro-inflammatory cytokine release from monocytederived macrophages of the newly born, compared to equimolar levels of IL-10. These
findings may help explain why DEX, when used at a low dose and short course, for selected
patients with advanced BPD, has limited efficacy34, 35. None of these three agents, had an
inhibitory effect on macrophage respiratory burst or phagocytosis, which may play a role in
the pathogenesis of BPD, at equimolar therapeutic levels of DEX. The relatively selective
effect of these three agents on pro-inflammatory cytokine release from macrophages of the
newborn, could tip the balance of inflammation towards recovery without jeopardizing the
newborn to infection. IL-10 has been used to treat adults with chronic inflammatory
disorders36. Therefore, the present study provides rationale for translational research using
airway instillation of IL-10 as potential therapy for BPD, in a manner similar to preclinical
and clinical work for surfactant laced with budesonide37.
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Figure 1. Dose-response of dexamethasone on pro-inflammatory cytokine release in endotoxinstimulated macrophages of the newly born

Cytokines were measured from cell culture media after pre-incubation with serial levels of
dexamethasone for 1 h followed by endotoxin stimulation for 18 h. Values are mean+/−SE,
N= 7, * = different from LPS alone, p< 0.01.
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Figure 2. Dose-response of betamethasone on pro-inflammatory cytokine release in endotoxinstimulated macrophages of the newly born
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Cytokines were measured from cell culture media after pre-incubation with serial doses of
betamethasone for 1 h followed by endotoxin stimulation for 18 h. Values are mean+/−SE,
N=7, *= different from LPS alone, p< 0.01.
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Figure 3. Dose-response of interleukin-10 (IL-10) on pro-inflammatory cytokine release in
endotoxin-stimulated macrophages of the newly born
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Cytokines were measured from cell culture media after pre-incubation with serial doses of
IL-10 for 1 h followed by endotoxin stimulation for 18 h. Values are mean+/−SE, N=7, * =
different from LPS alone, p< 0.01.
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Figure 4. Time course of pro-inflammatory cytokine release from endotoxin-stimulated
macrophages of the newly born: effect of anti-inflammatory agents and endogenous IL-10
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Cytokines were measured in cell culture media after pre-incubation with 10−8 M levels of
interleukin-10 (IL-10), dexamethasone (DEX), betamethasone (BETA), IL-10 monoclonal
antibody (IL-10 ab) or IgG control antibody followed by 4 h (open bars) or 18 h (black bars)
of endotoxin stimulation. Values are mean+/−SE, N =7, *= different from LPS alone
p<0.01, or += p<0.05.
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Figure 5. Effect of interleukin-10 (IL-10), dexamethasone (Dex) or betamethasone (Beta) on
phagocytosis by macrophages of the newly born
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Cytochalsin D was used as a positive control stimulus. Cells were pre-incubated for 1 h with
each anti-inflammatory agent at 10−8 M. Values are mean+/−SE, N=7 *= different from
PBS, p<0.01.
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Figure 6. Effect of interleukin-10 (IL-10), dexamethasone (Dex) or betamethasone (Beta) on
respiratory burst by macrophages of the newly born

Cells were pre-incubated for 1 h with each anti-inflammatory agent at 10−8 M. Values are
mean+/−SE, N=5, *= different from all other conditions with zymosan, p<0.01.
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